Quince Therapeutics Regains Nasdaq Compliance After Reporting $15.7M Equity
QNCX sits 32% above its 52-week low of $0.79 on light trading volume (0.2× avg).
Summary
Quince Therapeutics has officially regained compliance with Nasdaq's Market Value of Listed Securities (MVLS) rule, reporting $15.7 million in stockholders' equity. This positive development resolves a significant delisting risk that has plagued the company, following multiple non-compliance notices and a recent 1-for-10 reverse stock split. The Q1 2026 10-Q, filed on May 11, contained the financial figures that enabled this compliance determination.
At the time of this announcement, QNCX was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.79 to $45.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.